Multi-omic Characterization of Pancreatic Ductal Adenocarcinoma Relates CXCR4 mRNA Expression Levels to Potential Clinical Targets

Author:

Kocher Florian1ORCID,Puccini Alberto2ORCID,Untergasser Gerold1ORCID,Martowicz Agnieszka1ORCID,Zimmer Kai1ORCID,Pircher Andreas1ORCID,Baca Yasmine3ORCID,Xiu Joanne3ORCID,Haybaeck Johannes45ORCID,Tymoszuk Piotr6ORCID,Goldberg Richard M.7ORCID,Petrillo Angelica8ORCID,Shields Anthony F.9ORCID,Salem Mohamed E.10ORCID,Marshall John L.11ORCID,Hall Michael12ORCID,Korn W. Michael3ORCID,Nabhan Chadi3ORCID,Battaglin Francesca13ORCID,Lenz Heinz-Josef13ORCID,Lou Emil14ORCID,Choo Su-Pin15ORCID,Toh Chee-Keong15ORCID,Gasteiger Silvia16ORCID,Pichler Renate17ORCID,Wolf Dominik1ORCID,Seeber Andreas1ORCID

Affiliation:

1. 1Department of Internal Medicine V (Hematology and Oncology), Comprehensive Cancer Center Innsbruck (CCCI), Medical University of Innsbruck, Innsbruck, Austria.

2. 2Medical Oncology Unit 1, Ospedale Policlinico San Martino, Genoa, Italy.

3. 3Caris Life Sciences, Phoenix, Arizona.

4. 4Institute of Pathology, Neuropathology and Molecular Pathology, Medical University of Innsbruck, Innsbruck, Austria.

5. 5Diagnostic and Research Center for Molecular Biomedicine, Institute of Pathology, Medical University of Graz, Graz, Austria.

6. 6Data Analytics As a Service Tirol (DAAS) Tirol, Innsbruck, Austria.

7. 7West Virginia University Cancer Institute, Morgantown, West Virginia.

8. 8Medical Oncology Unit, Ospedale del Mare, Naples, Italy.

9. 9Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan.

10. 10Levine Cancer Institute, Carolinas HealthCare System, Charlotte, North Carolina.

11. 11Ruesch Center for The Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC.

12. 12Department of Hematology and Oncology, Fox Chase Cancer Center, Temple University Health System, Philadelphia, Pennsylvania.

13. 13Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California.

14. 14Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, Minnesota.

15. 15Curie Oncology, Mount Elizabeth Novena Specialist Centre, Singapore.

16. 16Department of Visceral, Transplant and Thoracic Surgery, Medical University of Innsbruck, Innsbruck, Austria.

17. 17Department of Urology, Medical University of Innsbruck, Innsbruck, Austria.

Abstract

Abstract Purpose: Chemokines are essential for immune cell trafficking and are considered to have a major impact on the composition of the tumor microenvironment. CX-chemokine receptor 4 (CXCR4) is associated with poor differentiation, metastasis, and prognosis in pancreatic ductal adenocarcinoma (PDAC). This study provides a comprehensive molecular portrait of PDAC according to CXCR4 mRNA expression levels. Experimental Design: The Cancer Genome Atlas database was used to explore molecular and immunologic features associated with CXCR4 mRNA expression in PDAC. A large real-word dataset (n = 3,647) served for validation and further exploratory analyses. Single-cell RNA analyses on a publicly available dataset and in-house multiplex immunofluorescence (mIF) experiments were performed to elaborate cellular localization of CXCR4. Results: High CXCR4 mRNA expression (CXCR4high) was associated with increased infiltration of regulatory T cells, CD8+ T cells, and macrophages, and upregulation of several immune-related genes, including immune checkpoint transcripts (e.g., TIGIT, CD274, PDCD1). Analysis of the validation cohort confirmed the CXCR4-dependent immunologic TME composition in PDAC irrespective of microsatellite instability–high/mismatch repair–deficient or tumor mutational burden. Single-cell RNA analysis and mIF revealed that CXCR4 was mainly expressed by macrophages and T-cell subsets. Clinical relevance of our finding is supported by an improved survival of CXCR4high PDAC. Conclusions: High intratumoral CXCR4 mRNA expression is linked to a T cell– and macrophage-rich PDAC phenotype with high expression of inhibitory immune checkpoints. Thus, our findings might serve as a rationale to investigate CXCR4 as a predictive biomarker in patients with PDAC undergoing immune checkpoint inhibition.

Funder

Medizinische Universität Innsbruck

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3